Medtronic Inc. said a U.S. jury ruled that its heart valve implant infringed a patent held by Edwards Lifesciences Corp. and awarded $392.5 million in damages.

Medtronic said it would appeal the ruling made by a jury in the Federal District Court of Delaware.

Medtronic said it expected U.S. approval for the CoreValve heart implant system by the end of its fiscal year ending April 2014.

Edwards shares rose as much as 4 percent to $73.42 on Wednesday on the New York Stock Exchange. Medtronic shares were up slightly at $59.64.